TCRの抗原同定とTCR遺伝子療法に向けた副作用予測の基盤構築

Keyphrases

1. T Cell Receptor 100%
2. Monoclonal Antibody 77%
3. Vesicular Stomatitis Virus 75%
4. Virus 71%
5. Rheumatoid Arthritis 64%
6. Arthritis 57%
7. T Cells 55%
8. Mouse Model 50%
9. Interstitial Lung Disease 50%
10. Cyclic Citrullinated Peptide 50%
11. Physiologic 50%
12. Recombinant 50%
13. Gut Dysbiosis 50%
14. High-throughput Detection 50%
15. Colorectal Cancer 50%
16. Specific Antigen 50%
17. PD-1 Expression 50%
18. Rabbit Monoclonal Antibody 50%
19. Anti-citrullinated Protein Antibodies 50%
20. B Cells 50%
21. Molecular Evolution 50%
22. SARS-CoV-2 Neutralizing Antibody 50%
23. COVID-19 50%
24. Citrus Virus 50%
25. Germ Cells 50%
26. SARS-CoV-2 Spike Protein 50%
27. Programmed Death-ligand 1 (PD-L1) 50%
28. West Nile Virus 50%
29. PMHC 50%
30. Ro52 50%
31. Soluble Peptides 50%
32. Antigen Receptor 50%
33. Antigen-specific 50%
34. Tumor-infiltrating Lymphocytes 50%
35. Connective Tissue Disease 50%
36. Porphyromonas Gingivalis (P. gingivalis) 50%
37. Autoantibodies 50%
38. Japanese Encephalitis 50%
39. Neutralization Test 40%
40. Chemiluminescence 40%
41. SKG Mouse 35%
42. Transgenic Mice 33%
43. Anti-cyclic Citrullinated Peptide Antibody (anti-CCP) 33%
44. Citrullinated Proteins 31%
45. Citrullinated Fibrinogen 28%
46. Antigen-specific T Cells 28%
47. Experimental Arthritis 27%
48. Citrullination 25%
49. Pseudotype 25%
50. Envelope Glycoprotein 25%
51. Heartland Virus 25%
52. Virus Envelope 25%
53. Joint Tissues 23%
54. Single-chain Trimer 21%
55. Japanese Encephalitis Virus 21%
56. Hospitalized Patients 20%
57. Virus Infection 20%
58. Patients with COVID-19 20%
59. Biosafety Level 3 20%
60. Pseudotyped Virus 20%
61. Whole Blood 20%
62. Immunofluorescence Assay 20%
63. Interleukin-6 17%
64. Neoantigen 16%
65. Inoculation 16%
66. Breast Cancer 16%
67. Intestinal Tissue 16%
68. CD8+ Tumor-infiltrating Lymphocytes 16%
69. Oligoclonal Bands 16%
70. High Sensitivity 14%
71. High Specificity 14%
72. Thrombocytopenia Syndrome 14%
73. Severe Fever 14%
74. Citrullinated Peptides 14%
75. Virus Detection 13%
76. Patient Morbidity 13%
77. TCR Repertoire 11%
78. Serum Samples 10%
79. Neutralizing Antibodies 10%
80. Fecal Microbiota Transplantation 10%
81. Luciferase 10%
82. Serum Blood 10%
83. Recombinant VSV 10%
84. Arginine Deiminase 10%
85. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 10%
86. Biosafety Level 10%
87. Live Virus 10%
88. Alternative Assays 10%
89. Highly Pathogenic 10%
90. Coronavirus 10%
91. Novel Coronavirus 10%
92. SARS-CoV-2 PCR 10%
93. Antibody Titer 10%
94. Laminarin 10%
95. Assay System 10%
96. Arthritis Score 10%
97. Enzyme-linked Immunosorbent Assay (ELISA) 10%
98. Joint Destruction 10%
99. Virus Proteins 9%
100. Coiled-coil Domain 9%
101. Antigenic Peptide 9%
102. Clinical Severity 9%
103. Citrus 9%
104. Mosaic Disease 9%
105. Anergic 8%
106. Anti-influenza 8%
107. Influenza nucleoprotein 8%
108. Ignorant 8%
109. Specific IgM 8%
110. Bone Marrow 8%
111. Citrullinated 8%
112. Cell Fraction 8%
113. Aβ Production 8%
114. Immune System 8%
115. Mature B Cells 8%
116. Rheumatoid Arthritis Patients 8%
117. Physiological Processes 8%
118. Entry Mechanism 7%
119. Safety Level 7%
120. Escherichia Coli 7%
121. Antibody Cross-reactivity 7%
122. Protein Refolding 7%
123. Human Infection 7%
124. Mortality Rate 7%
125. Neutralizing Monoclonal Antibody 7%
126. Citrullinated Antigens 7%
127. Next-generation Antibodies 7%
128. Meningoencephalitis 7%
129. Naïve B Cells 7%
130. Functional Peptides 7%
131. Recombinant Protein 7%
132. Synovial Tissue 7%
133. Mammalian Cells 7%
134. Immune-mediated Inflammatory Diseases 7%
135. High Reactivity 7%
136. Infected Individual 7%
137. High Concentration 7%
138. Primary T Cells 7%
139. Fully Human 7%
140. Control Method 7%
141. Human Neutralizing Antibody 7%
142. Flavivirus 7%
143. Mosquito-borne Diseases 7%
144. Phenotypic Characterization 7%
145. Hypermutation 7%
146. Flaviviridae 7%
147. Virus Serotype 7%
148. Single Guide RNA (sgRNA) 7%
149. Antibody Therapeutics 7%
150. Direct Quantification 7%
151. Immobilized Peptides 7%
152. Autoimmune 7%
153. Virus Neutralization 7%
154. Cell Systems 7%
155. Immune Complex 7%
156. Fibrinogen 7%
157. Binding Affinity 7%
158. Infected Cases 7%
159. Peripheral Blood Mononuclear Cells 7%
160. T Cell Lines 7%
161. Affinity Maturation 7%
162. High-throughput 7%
163. High Safety 7%
164. Treatment Group 7%
165. Oral Infection 6%
166. Knockout mutant 6%
167. Protein Production 6%
168. Gut Microbiota Composition 6%
169. Gingival Tissue 6%
170. Regulatory Mechanism 5%
171. Primary Tumor 5%
172. Adoptive Cell Therapy 5%
173. Autoreactive T Cells 5%
174. Metastasis 5%
175. Tumor Immunotherapy 5%
176. Tumor-specific T Cells 5%
177. Tumor Microenvironment 5%
178. Functional Analysis 5%
179. Intrinsic Properties 5%

Immunology and Microbiology

1. Antigen Specificity 100%
2. T Cell Receptor 100%
3. Vesiculovirus 75%
4. Arthritis 71%
5. Inflammatory Arthritis 70%
6. Neutralizing Antibody 57%
7. Monoclonal Antibody 57%
8. B Cell 55%
9. Major Histocompatibility Complex 50%
10. Connective Tissue 50%
11. Molecular Evolution 50%
12. Citrus 50%
13. Germ Cell 50%
14. Plant Virus 50%
15. Japanese Encephalitis 50%
16. Porphyromonas gingivalis 50%
17. Spike 50%
18. Protein Antibody 50%
19. Severe Acute Respiratory Syndrome Coronavirus 2 50%
20. West Nile Virus 50%
21. Leporidae 50%
22. Sensitive Detection 50%
23. Human Monoclonal Antibody 50%
24. Tumor-Infiltrating Lymphocytes 50%
25. Autoantibodies 50%
26. Mouse Model 50%
27. T Cell 48%
28. Immunology 46%
29. Fibrinogen 35%
30. Transgenic Mouse 28%
31. Immunoglobulin M 28%
32. Neutralization 27%
33. Glycoprotein 25%
34. Viral Envelope 25%
35. Chemoluminescence 22%
36. Citrullination 21%
37. Japanese Encephalitis Virus Group 21%
38. Japanese Encephalitis Virus 21%
39. Interleukin 6 20%
40. Intestine Flora 16%
41. COVID-19 16%
42. CD8 15%
43. Neoantigen 14%
44. Blood Plasma 14%
45. C-Type Lectin 12%
46. Phlebovirus 12%
47. Antigenicity 12%
48. Endocytosis 12%
49. ELISA 12%
50. Titer 11%
51. Viral Disease 11%
52. Immunofluorescence 11%
53. Coronavirinae 11%
54. Virus Detection 10%
55. Wild Type 10%
56. Feces microflora 10%
57. Nucleoprotein 7%
58. Mosaicism 7%
59. Protein Refolding 7%
60. Mortality Rate 7%
61. Cell Line 7%
62. Peripheral Blood Mononuclear Cell 7%
63. Virus Neutralization 7%
64. Cross-Reactivity 7%
65. Serotype 7%
66. Naive B Cell 7%
67. Influenza 7%
68. Escherichia coli 7%
69. Immune System 7%
70. Flaviviridae 7%
71. Binding Affinity 7%
72. Flavivirus 7%
73. Immune Complex 7%
74. Physiological Process 7%
75. Meningoencephalitis 7%
76. Affinity Maturation 7%
77. Feces 6%
78. Western Blot 5%
79. Infectious Agent 5%
80. Blood Level 5%
81. Enzyme-Linked Immunosorbent Assay 5%
82. SARS-related Coronavirus 5%
83. Antibody Titer 5%
84. Autoimmune Disease 5%
85. Epitope Mapping 5%
86. Cancer Immunotherapy 5%
87. Immunotherapy 5%